Liposome agents can specifically target tumors by binding to antibodies such as gender-affirming hormone (GAH), anti-EGFR, or anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibodies, small molecules such as folic acid and transferrin, or tumor-targeting peptides such as RGD rings [151–153]. This evidence concerns the gene ERBB2 and neoplasm.